Review paper<br>Cardiovascular safety of antihistamines

Anna Olasińska-Wiśniewska; Jerzy Olasiński; Stefan Grajek

doi:10.5114/pdia.2014.43191

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2014
vol. 31

Send email

Copy url:

abstract:

Review paper
Cardiovascular safety of antihistamines

Anna Olasińska-Wiśniewska

,

Jerzy Olasiński

,

Stefan Grajek

Postep Derm Alergol 2014; XXXI, 3: 182–186

DOI: https://doi.org/10.5114/pdia.2014.43191

Online publish date: 2014/06/13

View full text Get citation

Histamine is a mediator, which increases the permeability of capillaries during the early phase of allergic reaction, causes smooth muscle contraction of bronchi and stimulates mucous glands in the nasal cavity. Antihistamines are the basis of symptomatic treatment in the majority of allergic diseases, especially allergic rhinitis, allergic conjunctivitis, urticaria and anaphylaxis. The cardiotoxic effects of the two withdrawn drugs, terfenadine and astemizole, were manifested by prolonged QT intervals and triggering torsades de pointes (TdP) caused by blockade of the ‘rapid’ IKr potassium channels. These phenomena, however, are not a class effect. This review deals with a new generation of antihistamine drugs in the context of QT interval prolongation risk.

keywords:

Review paperCardiovascular safety of antihistamines

Anna Olasińska-Wiśniewska , Jerzy Olasiński , Stefan Grajek

histamine, H1 receptor, antihistamines, QT interval, torsades de pointes

Review paper
Cardiovascular safety of antihistamines

Anna Olasińska-Wiśniewska

,

Jerzy Olasiński

,

Stefan Grajek